Journal of Chemical Crystallography

, Volume 38, Issue 5, pp 387–392 | Cite as

X-ray Crystallographic Structures of Two Lamotrigine Analogues: (I) 3,5-Diamino-6-(2-chlorophenyl)-1,2,4-triazine Water Solvate and (II) 3,5-Diamino-6-(3,6-dichlorophenyl)-1,2,4-triazine Methanol Solvate

Original Paper

Abstract

The X-ray crystal structures of two lamotrigine derivatives (I) 3,5-diamino-6-(2-chlorophenyl)-1,2,4-triazine, C9H8ClN5, (465BL) as a hydrate, and (II) 3,5-diamino-6-(3,6-dichlorophenyl)-1,2,4-triazine, C9H7Cl2N5, (469BR) as a methanol solvate, have been carried out at liquid nitrogen temperature and room temperature, respectively. A detailed comparison of the two structures is given. Both are centrosymmetric with (I) in the orthorhombic space group Pbca, a = 12.2507(3), b = 15.7160(6), c = 21.71496(9) Å, Z = 16, and (II) in the monoclinic space group C2/c, a = 38.553(3), b = 4.9586(2), c = 14.546(2) Å, β = 111.59(1)°, Z = 8. Final R indices [I > 2sigma(I)] for (I) are R1 = 0.0670, wR2 = 0.1515 and for (II) R1 = 0.0434, wR2 = 0.1185. Structure (I) has water of crystallization in the lattice and (II) includes a solvated CH3OH. Structure (I) is characterized by having two crystallographically independent molecules, A and B, of 465BL, per asymmetric unit. Molecule B has a very unusual feature in that the 2-chlorophenyl ring is statistically disordered, occupying site (1) in 87.5% of the structure and site (2) in 12.5% of the structure. Sites (1) and (2) are related by an exact 180° pivot of the phenyl ring about the ring linkage bond. The presence of two independent molecules per asymmetric unit provides an ideal opportunity for the conformational flexibility of the molecule 465BL to be studied. Structure (I) also includes a further unusual feature in that the lattice contains one fully occupied water molecule and an additional solvated water which is only 33% occupied.

Index Abstract

Rex A. Palmer, Brian S. Potter, Michael J Leach and Babur Z. Chowdhry

The crystal structures of two lamotrigine analogues: (I) 3, 5-diamino-6-(2-chlorophenyl)-1, 2, 4-triazine, water solvate and (II) 3, 5-diamino-6-(3,6-dichlorophenyl)-1, 2, 4-triazine methanol solvate are presented. Structure (I) includes two molecules per asymmetric unit labeled A and B where molecule B is unusually disordered having Cl in either position 2 (87.5% occupied) or position 6 of the phenyl ring (12.5% occupied), the two sites being related by 180deg rotation about the ring linkage bond. Molecule I(A) on the other hand shows no disorder. The relative orientations of the two rings in I(A and B) and in II is shown to be different. Lamotrigine and analogues have been investigated for some time for their effects on the central nervous system. For example both lamotrigine and 5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine (code name BW 1003C87) are voltage-gated sodium channel blockers as well as blocking the release of the neurotransmitter glutamate. BW 1003C87 has also been shown to reduce the release of glutamate evoked by veratrine in brain tissue, providing a therapeutic approach in both cerebral ischemia and epilepsy [B. S. Meldrum, J. H. Swan, M. J. Leach, M. H. Millan, R. Gwinn, K. Kadota, S. H Graham, J. Chen, R. P. Simon , Brain Res., 1992, 593, 1.]. This is one of a series of papers on the structures of lamotrigine analogues.

Keywords

Central nervous system drugs Triazines Lamotrigines Voltage gated Na+ channel inhibitors Crystal structures and drug design 

References

  1. 1.
    Ettinger AB, Argoff CE (2007) Neurotherapeutics 4:75CrossRefGoogle Scholar
  2. 2.
    Gartwaite G, Brown G, Batchelor AM, Goodwin DA, Gartwaite J (1999) J Neurosci 94:1219CrossRefGoogle Scholar
  3. 3.
    Palmer AM, Carter N (2001) Drug News Perspectives 14:568CrossRefGoogle Scholar
  4. 4.
    Riddall DR, Leach MJ, Garthwaite J (2006) Mol Pharmacol 69:278Google Scholar
  5. 5.
    Malik S, Arif H, Hirsch LJ (2006) Expert Rev Neurother 6:1609CrossRefGoogle Scholar
  6. 6.
    Hooft RBV (1998) Nonius COLLECT: X-ray data collection and processing software user interfaceGoogle Scholar
  7. 7.
    Cosier J, Glazer AM (1986) J Appl Cryst 19:105CrossRefGoogle Scholar
  8. 8.
    Otwinowski Z, Minor W (1997) In: Carter CW Jr, Sweet RM (eds) Methods in enzymology: “macromolecular crystallography”, vol 276 (Part A). Academic Press, New York, p 307Google Scholar
  9. 9.
    Blessing RH (1995) Acta Cryst A51:33Google Scholar
  10. 10.
    Blessing RH (1997) J Appl Cryst 30:421CrossRefGoogle Scholar
  11. 11.
    Enraf-Nonius (1988) CAD-4 Software. Enraf-Nonius, Delft, HollandGoogle Scholar
  12. 12.
    North ACT, Phillips DC, Mathews FS (1968) Acta Cryst A24:351Google Scholar
  13. 13.
    Sheldrick GM (1996) SHELXS-86. Program for Crystal Structure Determination. Univ. of Göttingen, GermanyGoogle Scholar
  14. 14.
    Sheldrick GM (1997) SHELXL-97. Program for Crystal Structure Refinement. Univ. of Göttingen, GermanyGoogle Scholar
  15. 15.
    Farrugia LJ (1999) J Appl Cryst 32:837CrossRefGoogle Scholar
  16. 16.
    Spek AL (1990) Acta Crystallogr A46:C34Google Scholar
  17. 17.
    Barnes CL (1997) J Appl Cryst 30:568. [Based on ORTEP-III (v 1.0.3) by Johnson CK and Burnett MN]Google Scholar
  18. 18.
    Merrit EA, Bacon DJ (1997) Meth Enzymol 277:505 “Raster 3D Graphics version 2.7c.” [Implemented in WinGX (qv) and generated by Ortep-3 for Windows]Google Scholar
  19. 19.
    Macrae CF, Edgington PR, McCabe P, Pidcock E, Shields GP, Taylor R, Towler M, van de Streek J (2006) J Appl Cryst 39:453CrossRefGoogle Scholar
  20. 20.
    Ladd MFC, Palmer RA (2003) Structure determination by X-ray crystallography, 4th edn. Klewer-Plenum, NY, p 503Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.School of Crystallography, Birkbeck CollegeUniversity of LondonLondonUK
  2. 2.Medway School of ScienceUniversity of Greenwich (Medway Campus)Chatham MaritimeUK

Personalised recommendations